Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Pediatric Narcolepsy: A Primer for Clinicians Who Manage Children
Funke Afolabi-Brown, MD
Narcolepsy’s Burden of Illness: It’s Impact on the Child and Family
Anne Marie Morse, DO
Pediatric Narcolepsy: Psychological and Social Comorbidities
Kiran Maski, MD, MPH
Pediatric Narcolepsy: Physical Comorbidities
Evolving Therapy for Managing Pediatric Narcolepsy: Once-Nightly Sodium Oxybate
Evolving Therapy for Managing Pediatric Narcolepsy: Wake-Promoting Pitolisant
Can We Talk? Optimizing Patient and Parent/Caregiver Buy-in to the Management of Pediatric Narcolepsy
Advancements in GU Cancers: Key Data from AUA 2024
Jason Hafron, MD
Carissa Chu. MD
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Javier Cortes, MD, PhD
Komal Jhaveri, MD, FACP
ATTRv-PN: A Complicated Disease With a Poor Prognosis
John Berk, MD
Sami Khella, MD
ATTR Amyloidosis: Familial Vs Wild-Type
Noel Dasgupta, MD, FACC
Heads Up: It Might Be ATTRv Polyneuropathy – A Microlearning Course on Diagnosis and Treatment
Marcia Waddington-Cruz, MD, PhD
Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?
Advancing the Treatment of ATTRv-PN: What's in the Pipeline?
Current Pharmacologic Approaches to Managing Pediatric Narcolepsy
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Pediatric Patients with Narcolepsy
The Multiple Faces of ATTRv-PN
Diagnosing ATTRv-PN: What's in Your Toolbox?
Shh…Gene-Silencing Therapies for ATTRv-PN
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
Jeffrey V. Matous, MD
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Meghan Mooradian, MD
Loading...
We’re glad to see you’re enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.